Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 11/2015

01-11-2015 | Commentary

How to Improve the Safe and Effective Use of Doxorubicin in Children with Cancer

Author: John N. van den Anker

Published in: Clinical Pharmacokinetics | Issue 11/2015

Login to get access

Excerpt

Doxorubicin, one of the anthracyclines, is a chemotherapeutic agent widely used to treat several pediatric cancers such as acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, soft-tissue sarcoma, bone sarcoma, Ewing sarcoma, neuroblastoma, and Wilms tumor. As such, this drug has contributed substantially to the dramatic improvement of the 5-year survival rates for many of these childhood cancers [1]. …
Literature
1.
2.
Van der Pal HJ, van Dalen EC, Hauptmann M, Kok WE, Caron HN, van den Bos C, Oldenburger F, Koning CC, van Leeuwen FE, Kremer LC. Cardiac function in 5-years survivors of childhood cancer: a long-term follow-up study. Arch Intern Med. 2010;170:1247–55.PubMed
3.
Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: beginning with the end in mind. J Clin Oncol. 2010;28:1276–81.CrossRefPubMed
4.
Tukenova M, Guibout C, Oberlin O, Doyon F, Mousannif A, Haddy N, Guerin S, Pacquement H, Aouba A, Hawkins M, Winter D, Bourhis J, Lefkopoulos D, Diallo I, de Valthaire F. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28:1308–15.CrossRefPubMed
5.
Visscher H, Ross C, Rassekh S, Barhdadi A, Dube M-P, Al-Saloos H, Sander G, Caron H, van Dalen E, Kremer L, van der Pal H, Brown A, Rogers P, Phillips M, Rieder M, Carleton B, Hayden M. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2011;30:1422–8.CrossRefPubMed
6.
Visscher H, Ross C, Rassekh S, Sandor G, Caron H, van Dalen E, Kremer L, van der Pal H, Rogers P, Rieder M, Carleton B, Hayden M. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013;60:1375–81.CrossRefPubMed
7.
Völler S, Boos J, Krischke M, Würthwein G, Kontny N, Boddy A, Hempel G. Age-dependent pharmacokinetics of doxorubicin in children with cancer. Clin Pharmacokinet. 2015 (in press).
8.
Palle J, Frost B-M, Peterson C, Gustafson G, Hellebostad M, Kanerva J, Schmiegelow K, Lonnerholm G. Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs. 2006;17:385–92.CrossRefPubMed
9.
Lee J, Aminkeng F, Bhavsar A, Shaw K, Carleton B, Hayden M, Ross C. The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet. 2014;86:21–8.PubMedCentralCrossRefPubMed
10.
Gregers J, Green H, Christensen IJ, Dalhoff K, Schroeder H, Carlsen N, Rosthoej S, Lausen B, Schmiegelow K, Peterson C. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015 (Epub ahead of print).
Metadata
Title
How to Improve the Safe and Effective Use of Doxorubicin in Children with Cancer
Author
John N. van den Anker
Publication date
01-11-2015
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 11/2015
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-015-0300-4

Other articles of this Issue 11/2015

Clinical Pharmacokinetics 11/2015 Go to the issue

Review Article

Pharmacokinetics-Based Approaches for Bioequivalence Evaluation of Topical Dermatological Drug Products

Original Research Article

The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD

Review Article

Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis

Original Research Article

Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer

Original Research Article

Prediction of Fat-Free Mass in Children

Review Article

Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update